Table 2.
Margin status and tumour origin
| |
Duodenum |
Ampulla |
Distal Bile Duct |
Pancreas |
All tumour origins |
||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| |
NSP |
SP |
NSP |
SP |
NSP |
SP |
NSP |
SP |
NSP |
SP |
p-value |
| 9 | 5 | 58 | 12 | 27 | 18 | 35 | 11 | 129 | 46 | ||
| R1, n (%) |
1 (11%) |
2 (40%) |
19 (33%) |
5 (42%) |
15 (56%) |
17 (94%) |
25 (71%) |
10 (91%) |
60 (47%) |
34 (74%) |
0.002 |
| R0, n (%) |
2 (22%) |
3 (60%) |
7 (12%) |
7 (58%) |
3 (11%) |
1 (6%) |
1 (3%) |
1 (9%) |
13 (10%) |
12 (26%) |
|
| Rx, n (%) |
6 (67%) |
0 |
32 (55%) |
0 |
9 (33%) |
0 |
9 (26%) |
0 |
56 (43%) |
0 |
|
| Pancreas transection margin |
0 |
1 |
2 |
0 |
3 |
2 |
9 |
1 |
14 (11%) |
4 (9%) |
0.784 |
| DBD transection margin |
0 |
0 |
0 |
0 |
1 |
1 |
1 |
0 |
2 (2%) |
1 (2%) |
1.000 |
| SMA margin |
0 |
0 |
0 |
0 |
2 |
8 |
0 |
2 |
2 (2%) |
10 (22%) |
<0.001 |
| Posterior surface |
0 |
2 |
8 |
4 |
7 |
10 |
7 |
4 |
22 (17%) |
20 (44%) |
0.001 |
| SMV surface |
0 |
1 |
0 |
0 |
3 |
10 |
10 |
8 |
13 (10%) |
19 (41%) |
<0.001 |
| Anterior surface | 0 | 1 | 1 | 2 | 4 | 1 | 3 | 2 | 8 (6%) | 6 (13%) | 0.202 |
Margin status in 175 re-evaluated pancreaticoduodenectomies. NSP, non-standardized protocol. SP, standardized protocol. DBD, distal bile duct. SMA, superior mesenteric artery. SMV, superior mesenteric vein. For percentages and significances, calculations were made R0 vs R1 and Rx. In separate tumour origins, differences in R1-fraction between the SP-group and the NSP-group were significant in distal bile duct origin, (p = 0.006). Some NSP-cases were classified as R1 in an unspecified margin. R1-cases could have more than one involved margin. Bold text indicates p < 0.05.